NCT03882151 (EPILOG) is a NA clinical trial of electrical source imaging in Epilepsies, Partial, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

Who is sponsoring NCT03882151?

NCT03882151 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

What drugs are being tested in NCT03882151?

Interventions in NCT03882151: electrical source imaging.

What condition does NCT03882151 study?

NCT03882151 studies Epilepsies, Partial.

Is NCT03882151 still recruiting?

NCT03882151 is currently status unknown. Last updated 20 March 2019.

Last reviewed 2019-03-20 · How we verify

NCT03882151: EPILOG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy

Status unknown NA Last updated 20 March 2019

What this trial tests

NA trial testing electrical source imaging in Epilepsies, Partial in 30 participants. Status unknown.

Timeline

15 January 2019

Primary endpoint
1 June 2020

31 December 2020

Quick facts

Lead sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	15 January 2019
Primary completion	1 June 2020
Estimated completion	31 December 2020
Sites	2 locations across Belgium

Drugs / interventions tested

electrical source imaging

Conditions studied

Epilepsies, Partial — all drugs for Epilepsies, Partial →

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain — full company profile →

Who can join

Under 65, any sex, with Epilepsies, Partial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Drug resistant epilepsy is best managed by surgery. The goal of presurgical evalution is to correctly identify the epileptogenic zone, defined by the extent of cortical tissue that needs to be removed is order to achieve seizure freedom. When no causative lesion is identified, careful study of interictal activity is mandatory. Complementary analysis methods exist, designed to identify the source of electrical activity recorded with surface electro-encephalogram. While results are interesting in retrospective studies, the real clinical added value needs to be demonstrated with prospective studies. The company Epilog (Epilog, Ghent, Belgium) offers, with EPILOG PreOp®, a long-term EEG analysis to automatically detect epileptiform activity, combined with an estimation of the electrical source localization using a sLORETA inverse solution model. We will propose the EPILOG PreOp analysis to refractory epileptic patients with non-contributive cerebral imaging, under presurgical evaluation. By comparing the therapeutic decision with and without knowledge of the results of EPILOG PreOp®, we will establish the added clinical value of EPILOG PreOp®.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Epilepsies, Partial

Currently open trials in the same condition.

NCT06550726 — High-resolution Multi-parametric Magnetic Resonance Imaging for Focal Epilepsy · NA · recruiting
NCT06967012 — A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures · Phase 4 · recruiting
NCT06590896 — Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures · Phase 2 · recruiting
NCT05248269 — Thermocoagulation in Drug Resistant Focal Epilepsy · NA · active not recruiting
NCT04309812 — Transcranial Direct Current to Treat Epilepsy at Home · NA · active not recruiting

Other Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials

Trials by the same sponsor.

NCT07464938 — New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest · NA · recruiting
NCT07173036 — Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification Accordin · NA · not yet recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
NCT07588490 — Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments · NA · recruiting
NCT07161219 — Implementation of New Exercise Protocols in Cardiac Rehabilitation. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03882151 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Last refreshed: 20 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03882151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing